Is GLP-1 the same as cagrilintide ?

With the rapid expansion of the weight management drug market, new drug names are constantly emerging, often causing confusion. One common question is: Is cagrilintide the same as GLP-1? As a professional healthcare information provider, we will thoroughly analyze this important question to help you clearly understand cagrilintide's unique mechanism and therapeutic positioning.

Cagrilintide is a long-acting amylin analog. Amylin is a 37-amino acid peptide hormone secreted by pancreatic beta cells alongside insulin. Its primary

physiological functions include:

Slowing gastric emptying and prolonging satiety

Inhibiting postprandial glucagon secretion

Regulating appetite through central mechanisms

Synergizing with insulin to regulate postprandial blood glucose

It is noteworthy that in patients with type 2 diabetes and obesity, pancreatic insulin secretion often exhibits abnormalities, providing a theoretical basis for the development of insulin analogues.

Glucagon-like peptide-1 (GLP-1) is an incretin hormone primarily secreted by intestinal L cells, with functions including:

Stimulating glucose-dependent insulin secretion

Inhibiting glucagon secretion

Delaying gastric emptying

Potentially reducing appetite through central mechanisms

As a glucagon-like peptide-1 receptor agonist, cagrilintide primarily exerts its effects by activating the glucagon-like peptide-1 receptor:

1)Central Appetite Regulation: Acts on the hypothalamus and hindbrain regions to enhance satiety signals

2)Gastrointestinal Effects: Significantly slows gastric emptying and increases postprandial satiety

3)Glucagon Regulation: Suppresses inappropriate postprandial glucagon elevation

4)Potential Metabolic Benefits: May influence lipid metabolism and energy expenditure

GLP-1 agonists exert their effects by activating the GLP-1 receptor:

1)Insulin Regulation: Glucose-dependent promotion of insulin secretion

2)Delayed Gastric Emptying: Typically to a lesser extent than glucagon-like peptide-1 analogues

3)Central Effects: Limited penetration through the blood-brain barrier, primarily acting on brainstem regions

4)Cardiovascular Effects: Certain GLP-1 agonists demonstrate cardiovascular protective effects

1)GLP-1 agonists (using semaglutide as an example):

The STEP trial demonstrated an average weight loss of approximately 15% over 68 weeks

Primarily achieved by reducing caloric intake and potentially increasing energy expenditure

2)Cagrilintide (Early Data):

Preliminary studies indicate promising weight loss effects

Demonstrated synergistic effects when combined with semaglutide (REDEFINE trial)

May reduce appetite through mechanisms distinct from GLP-1 agonists

1.GLP-1 agonists:

Directly stimulate insulin secretion

Significantly reduce HbA1c (by 1.5–2.0% or more)

2.Cagrilintide:

Does not directly stimulate insulin secretion

Indirectly affects blood glucose by regulating gastric emptying and glucagon

May exhibit natural synergistic effects with insulin

Both drug classes may cause gastrointestinal side effects, though the specific effects may differ:

1.Common side effects of GLP-1 agonists

Nausea (15-40%)

Diarrhea (10-20%)

Vomiting (5-15%)

Typically diminish over time

2.Anticipated side effects of Cagrilintide (based on incretin-like properties)

Nausea (due to incretin-mediated gastrointestinal effects)

Potentially lower risk of hypoglycemia (does not directly stimulate insulin)

Specific safety profile requires further clinical trial data

1.The Established Position of GLP-1 Agonists

GLP-1 agonists have become: a primary and secondary treatment for type 2 diabetes, a key therapeutic category for obesity management, and certain agents have demonstrated cardiovascular benefits.

As a novel incretin mimetic, cagrilintide may offer:

1)Novel Mechanism of Action: Provides a new option for patients with inadequate response to GLP-1 agonists

2)Combination Therapy Potential: Complementary mechanisms with GLP-1 agonists may yield synergistic effects

3)Distinct Physiological Effects: May be particularly effective in controlling postprandial glucose and appetite

4)Long-acting characteristics: Designed for once-weekly dosing to enhance compliance

Despite these differences, cagrilintide and GLP-1 agonists do share some similarities, which may explain why they are sometimes confused:

Both are peptide hormone analogues
Both are used for weight management
Both affect gastric emptying and appetite
Both carry gastrointestinal side effects
Both are injectable formulations (based on current development formats)

Both target multiple pathophysiological defects in metabolic disorders

These similarities reflect a broader trend: modern metabolic disease treatment is evolving toward comprehensive, multi-hormone, multi-target strategies.

Perhaps the most exciting development lies in the combined use of these distinct classes of drugs. Preliminary studies indicate:

Cagrilintide + Semaglutide Combination Therapy:

Demonstrated superior weight loss compared to monotherapy in early trials

May enhance efficacy through complementary mechanisms

May allow for lower dosages, reducing side effects

This "dual-hormone" or "multi-hormone" approach represents the cutting edge of metabolic disease treatment, aiming to more comprehensively mimic normal physiological regulation.

1)Mechanism Understanding: Recognize that cagrilintide is a glucagon-like peptide-1 receptor agonist, not a GLP-1 receptor agonist.

2)Treatment Options: Different mechanisms may suit distinct patient subgroups.

3)Expected Side Effects: Both agents carry gastrointestinal side effects, though profiles may differ.

4)Dosage Considerations: Future combination therapies may emerge.

5)Personalized Medicine: Final selection should be based on patient characteristics, response, and tolerability.

No. Cagrilintide is a glucagon-like peptide-1 receptor agonist that differs fundamentally from GLP-1 agonists in chemical structure, mechanism of action, and receptor targets.

However, this distinction should not be viewed as competition but rather as an enrichment of the therapeutic arsenal. The true value of medical progress lies in offering more options for patients with diverse needs and creating potentially more effective combination strategies.

As cagrilintide undergoes further development and additional clinical trial data becomes available, we will gain clearer insight into its precise role within the metabolic disease treatment landscape. What is certain at present is that it represents an innovative approach based on distinct physiological pathways, potentially offering new hope for patients who respond inadequately to existing therapies.

For healthcare professionals and patients alike, the key lies in understanding these distinctions to make informed treatment decisions while maintaining an open mindset toward emerging therapeutic possibilities.

Disclaimer: This article is based on available scientific literature and clinical trial data as of early 2024. Cagrilintide remains in the research and development phase and has not yet received marketing approval from the FDA or other major regulatory authorities. All medical decisions should be made under the guidance of a healthcare professional. The information provided herein does not replace professional medical advice.

1.Frias, J. P., et al. (2021). *Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomized, phase 3 trial.* The Lancet, 398(10295), 143–155

2.Linneberg, H., et al. (2023). *Cagrilintide, a long-acting amylin analog, for weight management: Phase 2 dose-finding study.* Nature Metabolism, 5(4), 579–592.

3.Müller, T. D., et al. (2022). *The new biology of dual GIP and GLP-1 receptor agonism in obesity and beyond.* Nature Reviews Endocrinology, 18(10), 623–637.

4.American Diabetes Association 83rd Scientific Sessions (2023):

*Cagrilintide and semaglutide combination therapy: 48-week results from the REDEFINE trial.*

Mechanistic insights into amylin agonism and its metabolic effects.

5.Krause, M. P., & Saunders, D. (Eds.). (2023). Pharmacotherapy of Obesity: Emerging Targets and Therapies. Springer International Publishing.